Advances in therapy · 2026
Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison.
СтатьяСистематический обзорNetwork Meta-AnalysisСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cortesi Paolo A, Mezghani Marwa, Alshaikheid Mohammed, Lunk Izabella, D'Orsi Mario Fazzi, Zurria Monica, Bandello Francesco
Аннотация
INTRODUCTION: Despite the availability of various anti-vascular endothelial growth factor (anti-VEGF) therapies for diabetic macular edema (DME), high treatment burden remains a significant issue in many European countries, including Italy. This burden impacts healthcare costs, clinic capacities, and patient adherence. Aflibercept 8 mg was developed to reduce treatment burden by requiring only three monthly injections before allowing extended dosing intervals up to 6 months, without compromising efficacy and safety. This analysis aimed to evaluate the efficacy, safety, and treatment burden of aflibercept 8 mg regimens compared to other anti-VEGF options (aflibercept 2 mg, ranibizumab 0.5 mg, faricimab 6 mg, brolucizumab 6 mg, and bevacizumab 1.25 mg) in Italy.
METHODS: A systematic literature review identified randomised controlled trials of anti-VEGF therapies for DME with a 2-year follow-up. This informed a Bayesian network meta-analysis (NMA) assessing efficacy, safety, and treatment burden. A cost-minimisation analysis (CMA) was conducted from the perspective of the Italian National Health System over a 2-year horizon.
RESULTS: The NMA, involving nine studies, showed no significant differences in best-corrected visual acuity, anatomical outcomes, and safety between aflibercept 8 mg and the other anti-VEGF agents. Aflibercept 8 mg required fewer injections than the comparators, with a mean of 9.3 injections over 2 years for T&E (Q12) and 8.4 for T&E (Q16) regimens. Economically, aflibercept 8 mg was the least costly licensed and reimbursed anti-VEGF in Italy.
CONCLUSION: Aflibercept 8 mg may be the most advantageous anti-VEGF option for reducing treatment burden in Italian patients with DME, benefiting healthcare providers, clinics, and the healthcare system. Aflibercept 8 mg offers comparable efficacy and safety to other anti-VEGF therapies, with fewer injections and potentially lower overall costs.
METHODS: A systematic literature review identified randomised controlled trials of anti-VEGF therapies for DME with a 2-year follow-up. This informed a Bayesian network meta-analysis (NMA) assessing efficacy, safety, and treatment burden. A cost-minimisation analysis (CMA) was conducted from the perspective of the Italian National Health System over a 2-year horizon.
RESULTS: The NMA, involving nine studies, showed no significant differences in best-corrected visual acuity, anatomical outcomes, and safety between aflibercept 8 mg and the other anti-VEGF agents. Aflibercept 8 mg required fewer injections than the comparators, with a mean of 9.3 injections over 2 years for T&E (Q12) and 8.4 for T&E (Q16) regimens. Economically, aflibercept 8 mg was the least costly licensed and reimbursed anti-VEGF in Italy.
CONCLUSION: Aflibercept 8 mg may be the most advantageous anti-VEGF option for reducing treatment burden in Italian patients with DME, benefiting healthcare providers, clinics, and the healthcare system. Aflibercept 8 mg offers comparable efficacy and safety to other anti-VEGF therapies, with fewer injections and potentially lower overall costs.